Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
about
Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.Monoclonal antibodies: technologies for early discovery and engineering.Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.T-bet-expressing B cells during HIV and HCV infections.Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.The association of HIV-1 Gag-specific IgG antibodies with natural control of HIV-1 infection in individuals not carrying HLA-B*57: 01 is only observed in viremic controllers.CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.HIV integration sites and implications for maintenance of the reservoir.Case report: mechanisms of HIV elite control in two African women.Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope.Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in miceCurrent Treatment Options for HIV Elite Controllers: a Review
P2860
Q30352300-EF0A2186-BCF9-4354-9680-F1C495299D2DQ38633596-6E6223F4-4C0D-4FB9-AD5C-D2BF57BBE77BQ38673539-14118409-273D-4095-907E-4D70406E96FDQ39250593-39256617-59A8-4F1F-9A53-9A021B5C5394Q39454938-C57AAE02-B2C3-4745-843F-1CA28008FD42Q40120996-7B04A0C0-B84D-4A36-8CC9-2A1506601FC4Q40159913-01BF8116-A2B4-4B99-BA64-423E3D9ED156Q40163730-03450664-C812-43D2-9589-8B751CB43275Q45333913-4FEFEBE0-C8B0-41D8-9E00-DA9A0323F65CQ47110966-015A5930-1FC3-454C-A724-F21D9F70A69FQ47329569-9D16E902-97D3-4E14-B83C-495FF0270561Q47548873-1663519E-854D-46BA-A2B3-BEDDAC2BA813Q52338929-A4E2DE7F-9880-4FF1-875E-5D4EEECD0F6CQ53825583-BEAEBD32-34D1-4CAF-AD8A-455C04FC2105Q56974226-D26B1DD0-3E53-4F32-B650-F1A46D508D69Q57157197-B778249A-034D-4429-8689-772E1C9F7C6AQ57825309-0C3C7900-0096-4D4F-8B60-3F66314D068C
P2860
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Coexistence of potent HIV-1 br ...... iruses in a viremic controller
@ast
Coexistence of potent HIV-1 br ...... iruses in a viremic controller
@en
type
label
Coexistence of potent HIV-1 br ...... iruses in a viremic controller
@ast
Coexistence of potent HIV-1 br ...... iruses in a viremic controller
@en
prefLabel
Coexistence of potent HIV-1 br ...... iruses in a viremic controller
@ast
Coexistence of potent HIV-1 br ...... iruses in a viremic controller
@en
P2093
P2860
P50
P1476
Coexistence of potent HIV-1 br ...... iruses in a viremic controller
@en
P2093
Anthony P West
Ariel Halper-Stromberg
Dennis R Burton
Haoqing Wang
Harry B Gristick
Ildiko Toth
Joshua A Horwitz
Jovana Golijanin
P2860
P356
10.1126/SCITRANSLMED.AAL2144
P407
P50
P577
2017-01-01T00:00:00Z